The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1]. The trial investigated ...
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...
Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...
Sen. Sanders claims that the CEOs of major generic drugmakers said they produce and sell Ozempic for less $100 a month.
The ability to negotiate drug prices is part of a sweeping set of policies in President Joe Biden’s Inflation Reduction Act.